The U.S. Patent and Trademark Office granted orthobiologics company Kuros Biosciences a patent March 18 for the use of parathyroid hormone containing matrices for spinal fusion.
Three things to know:
1. The company's subsidiary Kuros Biosciences BV also secured a patent for developing an osteoinductive calcium phosphate, further bolstering its orthobiologics portfolio.
2. Kuros develops Fibrin-PTH, a natural fibrin-based healing matrix with an immobilized targeted bone growth factor. It is designed to apply onto and around an intervertebral body fusion device as a gel.
3. Fibrin-PTH is undergoing a Phase 2a clinical trial for single level transforaminal lumbar interbody fusion procedures in patients with degenerative disc disease, with autograft as the comparator.